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Abstract: Aneuploidy and overexpression of hsa-miR-155-5p (miR-155) characterize most solid and
hematological malignancies. We recently demonstrated that miR-155 sustains aneuploidy at early
stages of in vitro cellular transformation. During in vitro transformation of normal human fibroblast,
upregulation of miR-155 downregulates spindle checkpoint proteins as the mitotic checkpoint
serine/threonine kinase budding uninhibited by benzimidazoles 1 (BUB1), the centromere protein
F (CENPF) and the zw10 kinetochore protein (ZW10), compromising the chromosome alignment
at the metaphase plate and leading to aneuploidy in daughter cells. Here we show that the
heterogeneous nuclear ribonucleoprotein L (HNRNPL) binds to the polymorphic marker D2S1888 at
the 3′UTR of BUB1 gene, impairs the miR-155 targeting, and restores BUB1 expression in chronic
lymphocytic leukemia. This mechanism occurs at advanced passages of cell transformation and
allows the expansion of more favorable clones. Our findings have revealed, at least in part,
the molecular mechanisms behind the chromosomal stabilization of cell lines and the concept that,
to survive, tumor cells cannot continuously change their genetic heritage but need to stabilize the
most suitable karyotype.
Keywords: miR-155; BUB1; HNRNPL; CIN; CLL and microRNA
1. Introduction
Hsa-miR-155-5p (miR-155) contributes to genomic instability through downregulation of proteins
implicated in DNA mismatch repair, DNA damage repair, and maintenance of telomere integrity [1–3].
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We recently shed light on its involvement in the spindle assembly checkpoint (SAC) and chromosome
instability (CIN) during the early stages of the in vitro transformation of human normal dermal
fibroblasts (HDF) by hTERT and SV40 large T antigen-enforced expression [4–6]. We demonstrated
that miR-155 targets BUB1, CENPF and ZW10 [6], proteins implicated in preventing anaphase onset in
case of unattached kinetochores [7,8]. BUB1, the most studied of the three, is a serine/threonine kinase
localized at the outer plate of the kinetochore whose main function is to ensure the correct chromosome
alignment of the metaphase plate [8]. Indeed, BUB1 deregulation is strongly associated to aneuploidy
in mammalian cells [9–11]. Our data reflect the critical implications of CIN in tumor initiation [12–15],
highlighting miR-155 as a new player during tumor onset.
On the other hand, how CIN impacts the forward phases of tumor evolution is debated. Indeed,
it is not clear if there is a continuous increase of different chromosomal aberrations over time, with
the consequent positive selection of the fittest clones (“gradual” model); or if all the chromosomal
aberrations are generated in a short period of time followed by expansion of the most stable clones
(“crisis and stasis” model) [16,17]. The occurrence of equilibrium between the two mentioned models
could also be a plausible paradigm. However, how in the “gradual” model the fittest clones could
maintain a CIN behavior and continuously expand remains obscure. In this view, the “crisis and stasis”
paradigm seems more appropriate considering the stasis phase is a more stable genomic condition.
To better investigate this assumption, we evaluated CIN associated with the miR-155/BUB1 axis at
the late passages of our HDF immortalized models and in a cohort of patients with chronic lymphocytic
leukemia. We also investigated the mechanisms that could interfere with miR-155/BUB1 targeting, such
as the involvement of HNRNPL, an RNA-binding protein that hampers miRNAs’ action by binding
the target site on the miRNA [18,19].
2. Results
2.1. Role of miR-155 in Advanced Passages of Immortalized HDF Cells
To explore to what extent miR-155 affects aneuploidy in more advanced stages of transformation,
we analyzed chromosomes at different passages during the immortalization process of normal HDF cells
(HDFLT/hTERT cells at passages P16, P20 and P24) and found a similar number of karyotype abnormalities
at P16 and P20, but a higher number at P24 (Figure 1A). We next evaluated the morphology of the
metaphase plates of the same cells by immunofluorescence, considering abnormal those metaphases
that showed chromosomes with distinct spindle-positioning defects and incomplete congression [6].
We found an initially high rate of abnormal metaphase (P16) followed by a reduction at P20 and
P24 (Figure 1B). To better understand this apparent discrepancy, i.e., a higher number of aberrant
karyotypes with normal metaphase plates, we grouped the identified karyotypes by separating cells
with unique karyotypes from cells sharing a common karyotype or related karyotypes (considered
sub-clonal). The number of such clones and related sub-clones evolves from P16 to P24, whereas
single cells with aberrant karyotypes decrease (Figure 1C; Table S1). In summary, the most adaptive
clones expand during these passages, keeping normal metaphase plates. Considering these results,
we measured BUB1 protein expression during the multistep immortalization of HDFLT/hTERT cells
(from P14 to P24). In two of the three experiments, Western blotting showed an increase in BUB1
protein, despite the steadily high miR-155 expression (Figure 1D and Figure S1A,B), suggesting a
possible mechanism of escape from miR-155 targeting.
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Figure 1. Expansion of most adaptive clones with normal metaphase plates is associated with 
increase of BUB1 expression in the advance passages of HDFLT/hTERT cells. (A) Karyotype analysis and 
(B) metaphase analysis of HDFLT/hTERT cells at P16, P20 and P24 passages. For karyotype analyses, 
HDFLT/hTERT cells were arrested in mitosis by colcemid treatment (0.5 µg/mL for 4 h). A minimum of 
93 metaphases was considered in each experiment. For immunofluorescence, the cells were arrested 
in mitosis by nocodazole (75 ng/mL) for 17 h, plus 30 min of release; >150 metaphases were 
considered for each experiment. We considered abnormal those metaphases that showed errors in 
chromosomes congression with distinct defects of the kinetochore alignment respect to the 
metaphase plate. The percentages calculated are the result of eight technical replicates. (C) 
Visualization of the karyotype analysis of HDFLT/hTERT cell at P16, P20 and P24 passages with the 
fishplot package R. Each color represents a different karyotype identified at least twice in the 
metaphases analyzed (i.e., “46, XX”, normal karyotype; “47, XX, +7”, duplication of chromosome 7; 
“47, XX, +7, others”, duplication of chromosome 7 with others chromosome aberrations, etc.). 
Karyotype identified once were called “other karyotypes” and were represented in grey and light 
yellow. (D) Upper, Western blot analysis of BUB1 protein (120 kDa, blue line, P14-P24) and miR-155 
expression (red line, P13-P23) during the immortalization passages of HDFLT/hTERT cells. Linear 
regression of miR-155 (red dotted line) and of BUB1 protein expressions (blue dotted lines) are 
represented. The dotted line marked by the black arrow represents the miR-155 expression level in 
normal HDF at P17. BUB1 protein levels were quantified by Western blotting using γ-tubulin as 
loading control. 
2.2. The RNA-Binding Protein HNRNPL Correlates Positively with BUB1 in CLL Cells 
To evaluate the exclusivity of this miR-155/BUB1 targeting escape we tested in the same 
Western blot two other known miR-155 target proteins: mutL homolog 1 (MLH1) and mutS 
homolog 6 (MSH6) [1]. We found a recurrent modulation of these proteins during the passages 
(Figure S2A–C), supporting the hypothesis that miR-155 keeps its targeting function on those genes 
but loses that on BUB1. To test this hypothesis, we first analyzed the 3′UTR sequence of BUB1 and 
we found a CA repeat sequence ((CA)n), also known as the polymorphic marker D2S1888 
Figure 1. Expansion of most adaptive clones with normal metaphase plates is associated with increase
of BUB1 expression in the advance passages of HDFLT/hTERT cells. (A) Karyotype analysis and (B)
metaphase analysis of HDFLT/hTERT cells at P16, P20 and P24 passages. For karyotype analyses,
HDFLT/hTERT cells were arrested in mitosis by colcemid treatment (0.5 µg/mL for 4 h). A minimum
of 93 metaphases was considered in each experiment. For immunofluorescence, the cells were
arrested in mitosis by nocodazole (75 ng/mL) for 17 h, plus 30 min of release; >150 metaphases were
considered for each experiment. We considered abnormal those metaphases that showed errors in
chromosomes congression with distinct defects of the kinetochore alignment respect to the metaphase
plate. The percentages calculated are the result of eight technical replicates. (C) Visualization of
the karyotype analysis of HDFLT/hTERT cell at P16, P20 and P24 passages with the fishplot package
R. Each color represents a different karyotype identified at least twice in the metaphases analyzed
(i.e., “46, XX”, normal karyotype; “47, XX, +7”, duplication of chromosome 7; “47, XX, +7, others”,
duplication of chromosome 7 with others chromosome aberrations, etc.). Karyotype identified once
were called “other karyotypes” and were represented in grey and light yellow. (D) Upper, Western
blot analysis of BUB1 protein (120 kDa, blue line, P14-P24) and miR-155 expression (red line, P13-P23)
during the immortalization passages of HDFLT/hTERT cells. Linear regression of miR-155 (red dotted
line) and of BUB1 protein expressions (blue dotted lines) are represented. The dotted line marked by
the black arrow represents the miR-155 expression level in normal HDF at P17. BUB1 protein levels
were quantified by Western blotting using γ-tubulin as loading control.
2.2. The RNA-Binding Protein HNRNPL Correlates Positively with BUB1 in CLL Cells
To evaluate the exclusivity of this miR-155/BUB1 targeting escape we tested in the same Western
blot two other known miR-155 target proteins: mutL homolog 1 (MLH1) and mutS homolog 6
(MSH6) [1]. We found a recurrent modulation of these proteins during the passages (Figure S2A–C),
supporting the hypothesis that miR-155 keeps its targeting function on those genes but loses that
on BUB1. To test this hypothesis, we first analyzed the 3′UTR sequence of BUB1 and we found a
CA repeat sequence ((CA)n), also known as the polymorphic marker D2S1888 (rs113391170 at the
https://www.ncbi.nlm.nih.gov/snp). We focused on this marker because: (1) miR-155 is involved
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in microsatellite instability (MSI) in colorectal cancer by targeting hMLH1, MSH2 and MSH6 and
therefore potentially affecting the CA repeat sequence [1], and (2) the CA repeat may enable BUB1
mRNA to elude miRNA targeting by binding the RNA-binding protein HNRNPL depending on
the length of the marker [18,19]. We measured the length of the dinucleotide, at the genomic level,
during the transformation of HDFLT/hTERT cells by fragment length analysis (FLA), and observed an
induced instability from P19 to the last passage analyzed during HDF immortalization (Figure S3).
Over advanced passages of HDFLT/hTERT, we observed that the instability of the polymorphic CA
repeat correlated with increased BUB1 protein levels, suggesting that this mechanism affects later
passages of HDF immortalization. However, in the other two independent experiments, despite the
increased BUB1 expression in one of them, we did not register any instability of the D2S1888 marker
over the cell line passages. To better understand the role of this genetic locus in the regulation of
BUB1 expression, we next focused on human tumors, specifically on chronic lymphocytic leukemia
(CLL), for the following reasons: (1) the 2q13 chromosome region where BUB1 maps is associated
with CLL risk [20]; (2) we found two missense germline mutations in the BUB1 coding sequence in
two patients of a cohort of 30 CLL patients carrying 11q deletions (Figure 2); (3) BUB1 targeting by
miR-155 was also observed in a CLL cell line [6]; (4) HNRNPL binds the 3′UTR of BUB1 at the D2S1888
polymorphic marker in lymphoid cells (Figure S4) [21]. We investigated by FLA the D2S1888 marker
in DNA from PBMC of 172 CLL patients, 20 of whom had two longitudinal points (for a total of
212 samples), and 86 healthy donors, and found no significant differences in allele or homozygous
frequencies between these cohorts (Figure S5A,B). Then, given that B-CLL cells are the principal
altered component in CLL, we compared the D2S1888 genetic profiles of sorted CD3+ CD16+ cells and
leukemic cells from total PBMCs of the same patient and at two longitudinal points in two of the five
CLL patients with progressive disease. As shown in supplemental Figure S5C, we did not observe any
differences in D2S1888 between healthy and leukemic cell fractions nor during disease progression.
As previously mentioned, miRNA targeting could be regulated by the binding of HNRNPL to CA
repeats [18], and the affinity of HNRNPL to its RNA target is directly proportional to the length of the
(CA)n [22]. However, considering the stability of D2S1888, we evaluated HNRNPL and BUB1 protein
expression in longitudinal samples of PBMCs or pure B-CLL cells from 13 CLL patients (Table S2).
When the content of B cells was low or different between the sequential PBMC samples (CD5/CD19 <
70% of PBMC), B cells were purified. As shown in Figure 3, nine patients (70%) had an increase in
BUB1 protein levels over time. When we evaluated the relative miR-155 expression, except for patients
LLC05, we did not find correlations with BUB1 protein levels between the longitudinal time points.
These data are in line with the above-presented results on HDFLT/hTERT cells (Figure 1D). However,
we found a clear, positive correlation between BUB1 and HNRNPL protein expression in 12 out of
13 patients (92%; % = 0.6630; p = 0.0116) (Figure 3 and Figure S6A).
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Figure 2. BUB1 mutational analysis in CLL patients. Sequence analysis of BUB1 from peripheral 
blood mononuclear cells (PBMC) and cotton buccal swab specimens (SWAB) genomic DNAs from 
two CLL patients with BUB1 missense point mutations. Alignment was performed using the 
reference sequence NM_004336. 
Figure 2. BUB1 mutational analysis in CLL patients. Sequence analysis of BUB1 from peripheral blood
mononuclear cells (PBMC) and cotton buccal swab specimens (SWAB) genomic DNAs from two CLL
patients with BUB1 missense point mutations. Alignment was performed using the reference sequence
NM_004336.
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Figure 3. Positive correlation between BUB1 and HNRNPL protein expression in CLL patients. 
Western blots of BUB1 and HNRNPL proteins and RT-qPCR of miR-155 in longitudinal samples of 
purified B-CLL cells (LL05, LLC21, LLC34, LLC47, LLC76) and PBMC with > 70% of CD5/CD19 
positive cells (LLC31, LLC52, LLC62, LLC70, LLC81, LLC87, LLC98, LLC108) from CLL patients. 
Densitometric values normalized to β-actin expression are reported. Asterisks indicate time points 
with monoclonal B-cell lymphocytosis (MBL). MiR-155 relative expression was normalized to the 
endogenous reference RNU44 (2−Δct method). Data are means ± SD of three technical replicates. 
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To determine if HNRNPL interacts with BUB1 3′UTR in B-CLL cells as occur in T cells (Figure 
S4), we performed RNA immunoprecipitation (RIP) analysis in HG-3 cells, a CLL cell line in which 
we transfected the vectors carrying the BUB1 3′UTR with either 18CA or 19CA (the most 
representative alleles) downstream of the luciferase reporter gene. This analysis showed that 
specific binding of HNRNPL to the untranslated region of BUB1 RNA was stronger for 19CA than 
for 18CA (Figure 4A), as previously reported in a different cellular context [22]. We also observed, 
in two independent experiments, that HNRNPL silencing was correlated with a decrease in BUB1 
protein expression in HG-3 cells, while BUB1 mRNA levels did not change (Figures 4B, S6B). Thus, 
we propose that HNRNPL plays a significant role in the post-transcriptional regulation of BUB1. To 
define the interplay among miR-155, BUB1 and HNRNPL, we investigated the influence of miR-155 
on the BUB1 3′UTR after silencing HNRNPL in HG-3 cells. By inhibiting miR-155, the luciferase 
activity of the BUB1 3′UTR-reporter gene construct increased (~15%, p = 0.0034) only in HNRNPL-
depleted cells (Figure 4C). To further investigate the BUB1 3′UTR expression, we analyzed by RT-
PCR the 522 bp amplicon of the 3′UTR of BUB1 on HG-3 cells depleted of HNRNPL. We noticed an 
additional shorter PCR product of about 160 bp in both HNRNPL-depleted and control cells (Figure 
Figure 3. Positive correlation between BUB1 and HNRNPL protein expression in CLL patients. Western
blots of BUB1 and HNRNPL proteins and RT-qPCR of miR-155 in longitudinal samples of purified
B-CLL cells (L 05, LLC21, LLC34, LLC47, LLC76) and PBMC with > 70% of CD5/CD19 positive cells
(LLC31, LLC52, LLC62, LLC70, LC81, LC87, LC98, LLC108) from CLL patients. Densitometric
values n rmalized to β-actin expression are r po ted. Ast risks indicate time points with monoclonal
B-cell lymphocytosis (MBL). MiR-155 relative expression was normalized to the e dogenous reference
RNU44 (2−∆ct method). Data are means ± SD of thre tech ical replicat s.
2.3. HNRNPL Interaction on 3′UTR of BUB1 Inhibits miR-155 Targeting
To det rmine if HNRNPL interacts with BUB1 3′UTR in B-CL cells as oc ur in T cells (Figure S4),
we performed RNA immunoprecipitation (RIP) analysis in HG-3 cells, a CL cell ine in which we
transfected the vectors carrying the BUB1 3′UTR with either 18CA or 19CA (the most repr senta ive
alleles) downstream of the lucif rase reporter gene. This analysis showed th t pecific binding of
HNRNPL to the untranslated region of BUB1 RNA was stronger for 19CA than for 18CA (Figure 4A),
as previously reported in a different cellular context [22]. We also observed, in two indepen ent
experiments, that HNRNPL silencing was correlated with a decrease in BUB1 protein expression in
HG-3 cells, while BUB1 mRNA levels did not change (Figure 4B and Figure S6B). Thus, we propose
that HNRNPL plays a significant role in the post-transcriptional regulation of BUB1. To define the
interplay among miR-155, BUB1 and HNRNPL, we investigated the influence of miR-155 on the BUB1
3′UTR after silencing HNRNPL in HG-3 cells. By inhibiting miR-155, the luciferase activity of the
BUB1 3′UTR-reporter gene construct increased (~15%, p = 0.0034) only in HNRNPL-depleted cells
(Figure 4C). To further investigate the BUB1 3′UTR expression, we analyzed by RT-PCR the 522 bp
amplicon of the 3′UTR of BUB1 on HG-3 cells depleted of HNRNPL. We noticed an additional shorter
PCR product of about 160 bp in both HNRNPL-depleted and control cells (Figure 5A). This PCR
product was also observed in our HDFLT/hTERT cells during the immortalization, therefore cloned,
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sequenced and aligned to the genomic sequence of BUB1 gene (Figure 5B,C). We identified a new
spliced variant of the 3′UTR of BUB1, excluding the D2S1888 genetic locus but retaining the miR-155
binding site. To further establish the presence of this spliced variant, we designed specific PCR primers
(u58_F-4090_R; Figure 5C; Table S3) able to identify only this form to test its expression in eight PBMC
sequential samples from four different CLL patients. All the samples present the specific PCR product
of the spliced 3′UTR (Figure 5D). We analyzed by luciferase assay the susceptibility of the construct
containing the spliced form (BUB1 3′UTR SPL) to the miR-155. The luciferase activity increased about
100% (p < 0.0001) after ectopic expression of miR-155 antisense inhibitor (miR-155AS) on MEC-1 cells
and decreased over 100% (p < 0.0001) after miR-155 overexpression on HDFLT/hTERT cells (Figure 6A).
This demonstrated the interaction between the new variant of the 3′UTR of BUB1 and the miR-155,
suggesting that the post-transcriptional regulation of BUB1 is influenced by the local mRNA structure.
To assess this hypothesis, we evaluated changes in BUB1 protein levels by Western blotting in two
different B-CLL cell lines after miRNA or HNRPL loss of function using a “sponge” technique. Briefly,
HG-3 and MEC-1 cell lines were transfected with increasing doses of luciferase expression vectors
carrying either the spliced form or the full BUB1 3′UTR. As shown in Figure 6B, the BUB1 3′UTR SPL
vector, acting as a miR155-sponge, increases the endogenous BUB1 protein expression, derived by the
spliced form and/or by BUB1 mRNA not bound to HNRNPL, in a vector dose-dependent manner in
both cell lines. On the other hand, the luciferase vector containing the full BUB1 3′UTR acting as an
HNRNPL-sponge showed an essential reduction of the endogenous BUB1 expression with no evident
dose-dependent behavior. In this case depletion of HNRNPL probably permits the post-transcriptional
regulation of BUB1 by the miR-155 in both BUB1 mRNA forms, although we cannot exclude a different
miR-155 targeting of the two 3′UTR identified (Figure 7).
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Figure 4. HNRNPL binding to CA repeats influences BUB1 targeting by miR-155. (A) BUB1 3′UTR 
mRNA quantification in RNA immunoprecipitated with either the anti-HNRNPL or the anti-WT1 
antibody (as negative control) from HG-3 cells transfected as indicated. Data are means ± SD of 
three technical replicates normalized to the RNA input. p-value was calculated using the unpaired 
Student t-test, two-tailed. (B) Upper, protein expression levels of HNRNPL and BUB1 (120 kDa) in 
HG-3 cells transfected with either siRNA control (siCTRL) or siRNA of HNRNPL (siHNRNPL) for 
72 h; bottom, BUB1 mRNA relative expression was normalized to the endogenous reference β-actin 
(2−Δct method). Data are means ± SD of three technical replicates (C) Luciferase assay in HG-3 cells 
transfected with siRNA control or siRNA of HNRNPL for 48 h, and subsequently re-transfected 
with psiCHEK_2 3′UTR BUB1 (18CA) vector in combination with anti-miR Negative Control (NC) 
or anti-miR-155 (AS miR-155) for additional 24 h. Data are means ± SD of three technical replicates 
Figure 4. HNRNPL binding to CA repeats influences BUB1 targeting by miR-155. (A) BUB1 3′UTR
mRNA quantification i RNA immunoprecipitated with either the anti-HNRNPL or the anti-WT1
antibody (as egative control) fro HG-3 cells transfected as indicated. Data are means ± SD of three
technical replicates normalized to the RNA input. p-valu was calculated using the unpaired Student
t- est, two-tailed. (B) Upper, p otein xpression levels of HNRNPL and BUB1 (120 kDa) in HG-3 cells
transf cted wi h either siRNA control (siCTRL) or siRNA of HNRNPL (siHNRNPL) for 72 h; bottom,
BUB1 mRNA elative expression was normalized to the endogenous reference β-actin (2−∆ct method).
Data are means ± SD of three t chnical replicates (C) Luciferas assay in HG-3 cells transf cted with
siRNA contr l or siRNA of HNRNPL for 48 h, and subsequ ntly re-transfected with p iCHEK_2 3′UTR
BUB1 (18CA) vector n combi ati n with anti-miR Negative C ntrol (NC) or anti-miR-155 (AS miR-155)
for additional 24 h. Data are means ± SD of three technical replicates of three indep ndent transfections.
The p-value was calculated using the unpaired Student -test, two-tailed.
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Figure 5. BUB1 3′UTR characterization. (A) Detection of the ~522 and ~160 bp BUB1 3′UTR amplicons
by RT-PCR followed by gel electrophoresis in HG-3 cells after depletion of HNRNPL and (B) during
the immortalization of HDFLT/hTERT (1.5% agarose gel in 0.5× TBE buffer and ethidium bromide
staining). (C) Schematic representation of BUB1 3′UTR shows, from top to bottom: 3′ end of the
coding sequence (yellow arrow); NCBI/Ensembl reference 3′UTR sequence (green arrow); BUB1
3′UTR sequence identified in Pagotto et al. (blue box) [6]; D2S18888 polymorphic marker (black box);
predicted miR-155 binding site (red triangle); and PCR primers (black arrows). On the bottom, sequence
chromatograms of BUB1 3′UTR spliced form. (D) Detection of the ~95 bp amplicon of BUB1 3′UTR
spliced form by RT-PCR followed by gel electrophoresis in eight PBMC sequential samples from four
different CLL patients.
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Figure 6. miR-155 targeting of BUB1 3 ′UTR spliced form. (A) Relative luciferase activity in
HG-3 and HDFLT/hTERT cells after transfection with miR-155 precursor (miR-155), antisense inhibitor
oligonucleotide (AS miR-155), or respective negative controls (NC, negative control; and AS NC,
anti-sense negative control) as indicated. Values are means ± SD of three technical replicates of two
independent experiments. (B) Western blots of BUB1 in HG-3 and MEC-1 cell lines transfected with
increasing doses of luciferase vectors carrying the spliced form (SPL) or the full BUB1 3′UTR (23CA).
Densitometric values, normalized to β-actin expression, are showed by line charts (SPL, red line; 23CA,
black line; linear regressions, dotted lines).
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Figure 7. Graphical representation of the proposed model of miR-155/HNRNPL/BUB1 axis. The targeting
of BUB1 by miR-155 could be regulated by the binding of HNRNPL to the CA repeats in the BUB1
3′UTR, hindering the availability of the miR-155 binding site. In the shorter form of the 3′UTR of
BUB1, HNRNPL cannot bound the 3′UTR, permitting the post-transcriptional regulation of BUB1 by
the miR-155.
3. Discussion
Chromosomal abnormalities are present in 60–80% of the human tumors [23,24], making CIN
one of the most studied hallmark of cancer. CIN is positively correlated with tumor stage, relapse,
metastasis, treatment and resistance [25,26], and is predominately caused by defects in the mitotic
chromosome segregation [27]. However, despite the relevance of CIN in cancer, its role in the evolution
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of tumors seems contradictory since an excessive and extensive CIN is incompatible with life, even for
neoplastic cells [28]. To explain this phenomenon seems indispensable to optimize tumor fitness by
attuning CIN, with an intricate interplay between cellular selection and molecular activation [29,30].
We recently described how mir-155 targets BUB1, CENPF and ZW10 during the early stages of
cellular transformation and causes cellular aneuploidy [6]. However, at more advanced stages of
in vitro transformation, we witness an increase of normal metaphases despite the expansion of cells
with abnormal karyotypes and the consistently high expression of miR-155. To explain this apparent
discrepancy, we supposed a possible miR-155 two-step mechanism to sustain cellular transformation:
initially its upregulation induces chromosome instability targeting genes of the mismatch repair, such
as hMLH1, MSH2 and MSH6 [1], and genes involved in the SAC of the cell cycle, such as BUB1,
CENPF and ZW10 [6]; then, once we induced the fittest genetic abnormalities, a second step of genomic
stabilization can be supported by inducing MSI at the 3′UTR of BUB1 gene to impair miR-155 targeting
and restore BUB1 expression. However, this hypothesis was not verified in our CLL model, which,
to restore BUB1 expression, uses another mechanism or rather increases the expression of the RNA
binding protein HNRNPL, which binds the BUB1 3′UTR and impairs miR-155 targeting. Therefore,
in B-CLL cells where miR-155 is upregulated [31], BUB1 and HNRNPL are positively correlated, and
mostly they both increase over time (Figure 3). Our data show the importance of BUB1 to maintain the
stability of aneuploidy cancer cells, and are in line with papers that show (i) the key role of BUB1 in
maintaining human cell viability in the near haploid cell line HAP-1, which is derived from the chronic
myeloid leukemia KBM-7 cell line [32]; (ii) the robust spindle check point of aneuploid colon cancer
cell lines [33]; and (iii) the capacity to sensitize tumor cells to taxanes, ATR and PARP inhibitors by
hindering BUB1 activity in triple-negative breast cancer in vitro and in vivo models [34].
4. Materials and Methods
4.1. Primary Cells
Blood samples from healthy donors (HD) were obtained at the “Centro di Riferimento Regionale
di Genetica Medica” (Chieti, Italy), while blood samples from Chronic Lymphocytic Leukemia (CLL)
patients were obtained from “Policlinico Universitario Agostino Gemelli” (Rome, Italy) and biobanks
of the CLL Research Consortium (UCSD, San Diego, CA, USA). HD and CLL patients gave written
informed consent for the use of their samples for research purposes, in accordance with the Declaration
of Helsinki. The study protocols were approved by the institutional review board of the “G. d’Annunzio”
University of Chieti-Pescara (18_verb.12.07.2018), the “Policlinico Universitario Agostino Gemelli” of
Rome (P/948/CE/2011; P/392/CE/2012; 0015023/16) and UCSD (171884CX), respectively.
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation
with Ficoll-Paque Plus (GE Healthcare, Chicago, IL, USA). B-CLL cells purification was performed
using B Cell Isolation Kit II, human (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions.
4.2. DNA/RNA Extraction and Reverse Transcription Quantitative PCR (RT-qPCR)
DNA was extracted from cell lines, blood samples, PBMC and B-CLL cells using the PureLink®
Genomic DNA Kit (Thermo-Fisher Scientific, Waltham, MA, USA), QIAamp DNA Blood Kit
(Qiagen, Hilden, Denmark), or by Phenol-chloroform extraction. DNA quality was assessed by
gel electrophoresis on 0.8% agarose gel electrophoresis in 0.5× Tris borate EDTA (TBE) buffer in the
presence of ethidium bromide. Total RNA was isolated from cells using QIAzol Lysis Reagent (Qiagen,
Hilden, Denmark) according to the manufacturer’s instructions. RNA quantification was performed
by NanoDrop 2000 (Thermo-Fisher Scientific, Waltham, MA, USA). MiR-155 was reverted from 25 ng
of total RNA using specific reverse primers (stem loop RT primers designed with modifications to
include the UPL #21 (Roche, Basel, Switzerland, complementary sequences; Table S3) and the TaqMan
Micro-RNA Reverse Transcription Kit (Thermo-Fisher Scientific, Waltham, MA, USA). Reactions were
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incubated 30 min at 16 ◦C, followed by pulsed RT of 60 cycles at 30 ◦C for 30 s, 42 ◦C for 30 s, and 50 ◦C
for 1 s [35]. Reverse transcription quantitative PCR was performed on the CFX96 Touch™ Real-Time
PCR Detection System (Bio-Rad, Hercules, CA, USA), using the Universal Mastermix (Roche, Basel,
Switzerland). Target amount, normalized to the endogenous reference RNU44 was determined using
the 2−∆ct method (User Bulletin #2, Applied Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA).
4.3. Cell Culture
MEC-1 and HG-3 cell lines were acquired from Leibniz Institut DSMZ—the German Collection of
Microorganisms and Cell Cultures, Inhoffenstraße 7B, 38124 Braunschweig, Germany- (December 2015
and February 2016, respectively). Cells were cultured in RPMI medium supplemented with 10% fetal
bovine serum, 1% Pen/Strep and 1% L-glutamine (Sigma-Aldrich, Saint Louis, MO, USA) at 37 ◦C in a
5% CO2 incubator. Normal human adult dermal fibroblasts (HDFa, Thermo-Fisher Scientific, Waltham,
MA, USA) were immortalized using retroviruses (RV LTSV40 and RV hTERT) in combination with
antisense of miR-155 or control lentiviruses (LV AS miR-155, LV CTRL), as described in Pagotto et
al. [6]. Briefly, normal HDF cells were infected at passage #4 (P4), with the retrovirus transducing the
SV40 Large T antigen for 3 h, then they were infected overnight with LV pmiRZip AS miR-155 and
LV pmiRZip CTRL (System Biosciences, Palo Alto, CA, USA). Then, the cells were selected for seven
days with puromycin (0.5 µg/mL) (Santa Cruz Biotechnology, Dallas, TX, USA). After selection the
cells were infected at passage #6 (P6) with the retrovirus transducing the hTERT gene for 3 h. Then
hygromycin selection was performed for an additional seven days (50 µg/mL) (InvivoGen, San Diego,
CA, USA). Since LV AS CTRL contains the copGFP reporter gene, GFP-positive cells were sorted using
the FACSAriaIII, 100 µm nozzle (BD Biosciences, Becton, Dickinson and Company, Franklin Lakes, NJ,
USA). Immortalized HDF cells infected with LV AS miR-155 were not considered in this paper whereas
the LV CTRL immortalized HDF cells were named: HDFLT/hTERT. HDFLT/hTERT cells were cultured
in Medium 106 (M106) supplemented with Low Growth Serum Supplement (LSGS) (Thermo-Fisher
Scientific, Waltham, MA, USA).
4.4. Plasmids
The spliced 3′UTR region of BUB1 gene was amplified by PCR from HDF genomic DNA and cloned
into a pGL3-Control firefly luciferase reporter vector using the XbaI restriction enzyme immediately
downstream of the luciferase gene (pGL3_3′UTR BUB1 SPL, Promega, Madison, WI, USA). The 3′UTR
regions of BUB1 gene with different CA repeats were cloned downstream the Renilla luciferase gene in
the psiCHECK_2 vector (psiCHECK-2_3′UTR BUB1 (CA)n, Promega, Madison, WI, USA), as described
in Pagotto et al. [6].
4.5. Cells Transfection and Luciferase Target Assays
Transfections of MEC-1 and HG-3 cells were performed using Amaxa™ Nucleofector™ II
(Lonza, Basel, Switzerland), program U-016; U-023 for HDFLT/hTERT cells. Briefly, 1–5 × 106 cells
were transfected with plasmid DNA (2 µg/L Million of cells); and/or with the antisense inhibitor
oligonucleotide, AS miR-155: ID:AM12601 (200 nM final concentration in the culture media); or miR-155
precursor (100 nM final concentration in the culture media), ID:PM12601 and respective negative
controls AS NC and NC (Thermo-Fisher Scientific, Waltham, MA, USA)). The HNRNPL knockdown
gene expression was performed on HG-3 cells using small interfering RNAs (hNRNPL siRNA (h),
or Control-siRNA-A, Santa Cruz Biotechnology, Dallas, TX, USA) at a final concentration of 200 nM in
2 mL of culture media per well/sample. Firefly and Renilla luciferase activities were measured using
the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer’s
instructions. To control the transfection efficiency, Renilla luciferase activity was normalized to firefly
luciferase activity.
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4.6. Mutational Analysis
DNA sequencing was performed using the Big Dye Terminator v3.1 (Thermo-Fisher Scientific,
Waltham, MA, USA) in an automated DNA capillary ABI 3130 XL sequencing machine (Applied
Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA). Primers were designed to amplify all the
exons of BUB1 and the regions surrounding them (Table S3), and for the identification of mutations the
sequenced data were compared against published BUB1 gene sequences in GenBank.
4.7. Western Blotting
Cells samples were washed two times with cold PBS, and lysed in cold NIH buffer (1% Igepal,
1 mM EDTA, 50 mM TrisHCl, 150 mM NaCl) supplemented with proteases and phosphatase inhibitors
(Protease Cocktail, Phosphatase Inhibitor Cocktail, Sigma-Aldrich, Saint Louis, MI, USA). Cell lysates
were cleared by centrifugation (15 min at 14,000× g at 4 ◦C), then loaded on a Criterion TGX 4–20%
precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA) and transferred onto a PVDF membrane
(Bio-Rad, Hercules, CA, USA). Primary antibodies used were: anti-BUB1 (B3), anti-γ-tubulin (C-20),
anti-hnRNPL (4D11) (Santa Cruz Biotechnology, Dallas, TX, USA) and β-actin (Sigma-Aldrich, Saint
Louis, MI, USA). Expression was detected using ECL chemiluminescent substrate (Thermo-Fisher
Scientific, Waltham, MA, USA) after treating with specific HRP-conjugated secondary antibody (Cell
Signaling Technology, Danvers, MA, USA). To quantify Western blot signals, high resolution of
autoradiography digital images were acquired and band signals were quantified by ImageJ (Fiji
software, 1.51 version, https://fiji.sc/).
4.8. Karyotype Analyses
To prepare metaphase spreads, 1–2 × 106 HDFLT/hTERT cells of different passages (P16/P20/P24)
were plated onto 35-mm dishes with glass slides (Amniodishes, Euroclone, Pero, Milano, Italy),
respectively. After 24 h, was carried out the colcemid treatment (Irvine Scientific, Santa Ana, CA, USA):
0.5 µg/mL for 4 h at 37 ◦C in an atmosphere of 5% CO2 and 20% humidity. Cells were then fixed in
Carnoy’s solution (75% methanol, 25% acetic acid) and stained with Giemsa solution (5% for 10 min).
Digital images were analyzed by Genikon software (3.8 version, Nikon, Shinagawa, Tokyo, Japan).
The graphic representation of changes of sub-clonal populations over time was performed using the
fishplot package for R [36].
4.9. Immunofluorescence
To visualize aberrant metaphase plates, HDFLT/hTERT cells at different passages (P16/P20/P24) were
seeded at mid-confluence in eight-well BD Falcon™CultureSlides (7 × 103 cells for well) (BD Bioscience,
Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Cells were arrested at pro-metaphase with
75 ng/mL of nocodazole (Sigma-Aldrich, Saint Louis, MI, USA) for 17 h plus 30 min of release, and
prepared for immunofluorescence analysis as previously described in Pagotto et al. 2018 [6]. More
than 150 images of metaphases were randomly acquired. Primary antibodies: anti alpha-tubulin
(ab7291, Abcam, Cambridge Science Park, UK) and human anti-CREST (Antibodies Inc., Davis, CA,
USA). Secondary antibodies: cross-adsorbed species-specific fluorescent secondary antibodies (Bethyl
Laboratories, Montgomery, TX, USA). DNA was detected using DRAQ5 (Cell Signaling Technology,
Danvers, MA, USA). All the images were acquired using a Carl Zeiss LSM5 Pascal confocal laser
scanning microscope (Carl Zeiss 63× Plan Neofluar oil-immersion objective, Oberkochen, Germany).
4.10. RNA-Binding Protein Immunoprecipitation (RIP)
RIP was performed with Magna RIP kit (Millipore, Burlington, MA, USA). The assay was
performed essentially according to the manufacturer’s instructions using 17 million HG-3 cells as
the starting material. Magnetic beads (50 µL) were incubated for 30 min at room temperature with
5 µg of anti-HNRNPL antibody (4D11) or anti-WT1 antibody (F6) as negative control (Santa Cruz
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Biotechnology, Dallas, TX, USA), and then overnight with 100 µL of cell lysate at 4 ◦C. RNA was
extracted using the miRNeasy Micro Kit and RNase-Free DNase Set (Qiagen, Hilden, Denmark) to
perform a DNase digestion during RNA purification. The precipitated RNA was reverse-transcribed
with and without reverse transcriptase to exclude plasmid DNA contamination. RT-qPCR was
normalized to the non-IP control (input).
4.11. DNA Fragment Length Analysis (FLA)
FLA of DNA from 172 CLL patients, 20 of whom had two longitudinal points (for a total
of 212 samples), 86 healthy donors, and HDFLT/hTERT cells at different passages was performed
using fluorescent D2S1888F_6FAM labeled forward primer and unlabeled reverse primer BUB1_3759
(Table S3) on an ABI 3130 XL sequencing machine with ABI Standard Dye Set DS-33 and the GeneScan™
500 LIZ® (Thermo-Fisher Scientific, Waltham, MA, USA).
4.12. Statistical Analyses
Data regarding RT-qPCR, RIP and luciferase assays were evaluated using two-tailed Student’s
t-tests, based on the significance obtained by the Shapiro-Wilk Normality Test. Analysis of correlation
between BUB1 and HNRNPL protein was performed by non-parametric Spearman’s correlation,
two-tailed. All RT-qPCR assays were performed in triplicate. A p-value > 0.05 was considered not
significant (ns); the significant p-values are reported in the figures. When indicated, standard deviation
(SD) is represented by a scale bar on graphs.
5. Conclusions
We unraveled an important role of BUB1 in CLL, underlined by two germline mutations in the
BUB1 coding sequence in a series of 30 CLL cases, and demonstrated that BUB1 protein expression
correlates with HNRNPL expression.
Our data support the hypothesis of a “tuning CIN to optimize tumor fitness” [29] by elucidating
a novel molecular mechanism that highlight the role of the RNA binding protein HNRNPL as the
tiebreaker for the miR-155 targeting of BUB1. It is interesting to note that miR-155 is an essential
microRNA during inflammation [37,38], as was also evidenced for HNRNPL [39,40] and cellular
aneuploidy [26,41], suggesting our finding as a novel dynamic molecular link between inflammation
and cancer [42].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/575/s1,
Table S1: Karyotype of HDFLT/hTERT cells at passages 16, 20 and 24, Table S2: Genetic, molecular and clinical
features of the B-CLL patients, Table S3: Oligonucleotide primers used in the study for microRNA expression
(miRE), mutational analysis (MA), reverse transcription (RT) and gel electrophoresis (Gel), Figure S1: A and B,
Western blot analysis of BUB1 protein expression during the immortalization passages of HDFLT/hTERT cells in two
independent experiments, Figure S2: A, B and C, Western blotting analysis of MSH6 and MLH1 proteins during
the immortalization passages of HDFLT/hTERT cells in the three independent experiments showed in Figure 1D
and supplementary Figure S1, Figure S3: Fragment length analysis (FLA) of the D2S18888 polymorphic marker in
immortalized HDF cells, Figure S4: Screen shot of the UCSC Genome Browser showing the HNRNPL binding
sites on the BUB1 gene (BUB1 exons and UTRs are represented by blue boxes) in CD4 positive cells, Figure S5: A,
total allele frequency and B, homozygous frequency of the D2S18888 polymorphic marker length in DNA samples
from healthy donors (HD) and CLL patients, analyzed by fragment length analysis. C, Electropherograms of the
D2S1888 amplicon in DNA from total (PBMC), normal (CD3/CD16 positive cells) and leukemic (B+) cell fractions
from two patients (LLC47 and LLC81) at different stages of disease, Figure S6: A, Graphical representation of
the correlation analysis between BUB1 and HNRNPL protein expression in the CLL patients listed in Figure 3.
For each patient, the relative protein expression is related to the first time point value (first time point = 1).
Analysis of correlation was performed by non-parametric Spearman’s correlation, two-tailed. B, Western blots
of BUB1 (120 kDa) and HNRNPL proteins and BUB1 mRNA relative expression in HG-3 cells transfected with
either siRNA control or siRNA of HNRNPL for 72 h. All the raw data used to prepare this manuscript are freely
available at the code hosting platform GitHub (https://github.com/VeroneseVisoneLabs/HNRNPL-restrains-miR-
155-targeting-of-BUB1-to-stabilize-aberrant-karyotypes-of-transformed-cells).
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Abbreviations
miR-155 Hsa-miR-155-5p
BUB1 mitotic checkpoint serine/threonine kinase budding uninhibited by benzimidazoles 1
CENP-F centromere protein F
ZW10 zw10 kinetochore protein
HNRNPL heterogeneous nuclear ribonucleoprotein L
CLL chronic lymphocytic leukemia
SAC spindle assembly checkpoint
CIN chromosome instability
HDF human normal dermal fibroblast
HD healthy donors
PBMC Peripheral blood mononuclear cells
HDFLT/hTERT Immortalized HDF cells
FLA fragment length analysis
MLH1 mutL homolog 1
MSH6 mutS homolog 6
MSI microsatellite instability
MBL monoclonal B-cell lymphocytosis
RIP RNA immunoprecipitation
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